252 related articles for article (PubMed ID: 28849623)
1. Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents.
Noronha V; Joshi A; Patil VM; Banavali SD; Gupta S; Parikh PM; Marfatia S; Punatar S; More S; Goud S; Nakti D; Prabhash K
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e129-e137. PubMed ID: 28849623
[TBL] [Abstract][Full Text] [Related]
2. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
Mafodda A; Giuffrida D; Prestifilippo A; Azzarello D; Giannicola R; Mare M; Maisano R
Support Care Cancer; 2017 Sep; 25(9):2779-2786. PubMed ID: 28391437
[TBL] [Abstract][Full Text] [Related]
3. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.
Henry DH; Dahl NV; Auerbach M; Tchekmedyian S; Laufman LR
Oncologist; 2007 Feb; 12(2):231-42. PubMed ID: 17296819
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
[TBL] [Abstract][Full Text] [Related]
5. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia.
Steensma DP; Sloan JA; Dakhil SR; Dalton R; Kahanic SP; Prager DJ; Stella PJ; Rowland KM; Novotny PJ; Loprinzi CL
J Clin Oncol; 2011 Jan; 29(1):97-105. PubMed ID: 21098317
[TBL] [Abstract][Full Text] [Related]
6. Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron.
Lichtenstein GR; Onken JE
Dig Dis Sci; 2018 Nov; 63(11):3009-3019. PubMed ID: 30056562
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
Onken JE; Bregman DB; Harrington RA; Morris D; Acs P; Akright B; Barish C; Bhaskar BS; Smith-Nguyen GN; Butcher A; Koch TA; Goodnough LT
Transfusion; 2014 Feb; 54(2):306-15. PubMed ID: 23772856
[TBL] [Abstract][Full Text] [Related]
8. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
Reinisch W; Staun M; Tandon RK; Altorjay I; Thillainayagam AV; Gratzer C; Nijhawan S; Thomsen LL
Am J Gastroenterol; 2013 Dec; 108(12):1877-88. PubMed ID: 24145678
[TBL] [Abstract][Full Text] [Related]
9. Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study.
Valério de Azevedo S; Maltez C; Lopes AI
Scand J Gastroenterol; 2017 Jan; 52(1):29-33. PubMed ID: 27576956
[TBL] [Abstract][Full Text] [Related]
10. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.
Shepshelovich D; Rozen-Zvi B; Avni T; Gafter U; Gafter-Gvili A
Am J Kidney Dis; 2016 Nov; 68(5):677-690. PubMed ID: 27321965
[TBL] [Abstract][Full Text] [Related]
11. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
Toblli JE; Di Gennaro F
PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
[TBL] [Abstract][Full Text] [Related]
12. Oral vs intravenous iron therapy for postpartum anemia: a systematic review and meta-analysis.
Sultan P; Bampoe S; Shah R; Guo N; Estes J; Stave C; Goodnough LT; Halpern S; Butwick AJ
Am J Obstet Gynecol; 2019 Jul; 221(1):19-29.e3. PubMed ID: 30578747
[TBL] [Abstract][Full Text] [Related]
13. Intravenous iron sucrose v/s oral ferrous fumarate for treatment of anemia in pregnancy. A randomized controlled trial.
Bhavi SB; Jaju PB
BMC Pregnancy Childbirth; 2017 May; 17(1):137. PubMed ID: 28482869
[TBL] [Abstract][Full Text] [Related]
14. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
[TBL] [Abstract][Full Text] [Related]
15. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
[TBL] [Abstract][Full Text] [Related]
16. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial.
Auerbach M; Ballard H; Trout JR; McIlwain M; Ackerman A; Bahrain H; Balan S; Barker L; Rana J
J Clin Oncol; 2004 Apr; 22(7):1301-7. PubMed ID: 15051778
[TBL] [Abstract][Full Text] [Related]
17. Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial.
Froessler B; Cocchiaro C; Saadat-Gilani K; Hodyl N; Dekker G
J Matern Fetal Neonatal Med; 2013 May; 26(7):654-9. PubMed ID: 23130909
[TBL] [Abstract][Full Text] [Related]
18. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
[TBL] [Abstract][Full Text] [Related]
20. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial.
Singh H; Reed J; Noble S; Cangiano JL; Van Wyck DB;
Clin J Am Soc Nephrol; 2006 May; 1(3):475-82. PubMed ID: 17699248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
